Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "treatment"

3723 News Found

NATCO announces launch of Pomalidomide capsules in US
News | March 05, 2026

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma


Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy
R&D | March 05, 2026

Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy

The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales


MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai
News | March 05, 2026

MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai

A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer


Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows
News | March 05, 2026

Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows

Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality


Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy
Clinical Trials | March 05, 2026

Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy

SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum


Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Clinical Trials | March 03, 2026

Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings


AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
Clinical Trials | March 03, 2026

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population


Bioxytran reports 90% day-5 viral clearance in COVID-19 trial at highest dose of ProLectin-M
Clinical Trials | March 03, 2026

Bioxytran reports 90% day-5 viral clearance in COVID-19 trial at highest dose of ProLectin-M

Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile